(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Climbing Mount Everest: An Individual Victory - 2Figure out How to Assess the Unwavering quality of SUVs for Seniors
- 3From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- 4This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- 5Extraordinary Guinness World Records That Will Astound You
- Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- Investigating the Advantages of a Bank account: A Complete Aide
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 2025 Yachting Editors' Choice Awards: Yachts
- Share your pick for the miniature headphones that you generally suggest!
- Top notch Feasting: A Manual for Worldwide Acclaimed Eateries
- The race is on to turn your body into a GLP-1 factory
- 'Senseless violence' erupts at Christmas tree lighting; 4 injured
- Audits of 6 European Busssiness Class Flights
